Human CCL5/RANTES Standard (人趋化因子配体5 标准品)

CCL5 分子靶点信息概述

• 分子名：CCL5, C-C motif chemokine ligand 5
• 基因家族：Chemokine ligands
• 别名：RANTES; SISd; TCP228; MGC17164
• 曾用名：D17S136E; SCYA5
• 全称：T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; regulated upon activation, normally T-expressed, and presumably secreted; beta-chemokine RANTES; small inducible cytokine subfamily A (Cys-Cys), member 5; small inducible cytokine A5 (RANTES); chemokine (C-C motif) ligand 5

CCL5 分子靶点综述

趋化因子配体5(CCL5)，又名RANTES，是一种趋化细胞因子。它可趋化T细胞、嗜酸性粒细胞和嗜碱性粒细胞，在招募白细胞到炎症位点发挥着积极的作用。在T细胞释放的细胞因子如IL-2和IFN-γ的帮助下，CCL5可诱导某些自然杀伤细胞(NK)增殖和活化形成CC趋化因子活化的杀伤(CHAK)细胞。CCL5也是一种由CD8+T细胞释放的HIV抑制因子。最近，研究者正在开发完善乳酸菌体内产生CCL5的方案，以期其成为抑制HIV进入的局部杀菌剂。

人 Human CCL5 分子靶点信息

• 分子名：CCL5, C-C motif chemokine ligand 5
• 别称：
  • beta-chemokine RANTES
  • C-C motif chemokine 5
  • chemokine (C-C motif) ligand 5
  • D17S136E
  • eoCP
  • eosinophil chemotactic cytokine
  • MGC17164
  • RANTES
  • regulated upon activation, normally T-expressed, and presumably secreted
  • SCYA5
  • SIS-delta
  • SISd
  • small inducible cytokine A5 (RANTES)
  • small inducible cytokine subfamily A (Cys-Cys), member 5
  • small-inducible cytokine A5
  • t cell-specific protein P228
  • T-cell specific protein p288
  • T-cell-specific protein RANTES
  • TCP228
• 基因序列：NCBI_Gene: 6352
• 蛋白序列：UniProtKB: P13501

人 Human CCL5靶点分子功能（预测）

Enables several functions, including enzyme activator activity; phosphatidylinositol phospholipase C activity; and signaling receptor binding activity. Involved in several processes, including cellular response to cytokine stimulus; positive regulation of cell migration; and positive regulation of cell-cell adhesion. Acts upstream of or within positive regulation of T cell migration. Predicted to be located in cytoplasm. Predicted to be active in extracellular space. Implicated in several diseases, including hepatitis B; hepatitis C; liver disease (multiple); pulmonary tuberculosis; and severe acute respiratory syndrome. Biomarker of several diseases, including fatty liver disease (multiple); glucose metabolism disease (multiple); hypertension (multiple); liver cirrhosis (multiple); and lung disease (multiple).